We compared here the effectiveness of HSPG targeting with heparin used as a general soluble competitor, by testing NT4 and heparin for their effect on adhesion of different cancer cell lines to ECM supports and on cell growth, migration and colony formation of the same cell lines. The gene discussed is SDC2; the disease is cancer.